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DOPAMINE LEVELS IN THE BRAIN OF RAT MODELS OF 
HUMAN RHEUMATOID ARTHRITIS 
 
 
Amelia Stinson 
 
University of the Incarnate Word, 2017 
 
 
Research Focus. Rheumatoid arthritis is a chronic, debilitating, autoimmune disease that causes the 
destruction of bone tissue and the articular structures of joints. At least 30% of RA patient 
populations have cognitive impairment. Acidic dopamine (DA) is the principal 
neuroimmunotransmitter that links the central nervous system and peripheral nervous system 
together. The aim of the present study was to determine the levels of DA and its two acidic 
metabolites: 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in arthritic 
induced rats, and whether their levels vary across four different parts of the brain: amygdala, front 
cerebral cortex, hippocampus, and cerebellum. Brain protein was also assessed. 
Materials and Methods. 3-month old male Lewis Rats (n = 16) were randomized into either 
control (n = 10) or treatment (n = 6) groups. In the treatment group, arthritis was induced in the rats 
using Freund’s Adjuvant and all rats were sacrificed on day 28. Dopamine, DOPAC, and HVA 
levels were quantified using High Performance Liquid Chromatography technique while proteins 
were quantified using Bicinchroninic Acid Protein Assay, in the four brain regions. Two-way 
ANOVA test was performed to determine whether brain regions, induce arthritis treatment or their 
interactions significantly influenced the levels of the analytes (at p < .05). 
Research Results/Findings. Levels of brain protein (C-reactive protein) were elevated in arthritic 
rats across all brain regions (p > .05). Dopamine and DOPAC levels were lower in arthritic rats than 
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controls (p > 0.05). HVA levels were higher in arthritic rats compared to non-arthritic controls. 
Conclusions from Research. The present study has demonstrated that C-reactive protein, 
dopamine, DOPAC and HVA are involved in the neurophysiology of arthritis. RA patients can 
benefit from treatment with dopamine agonists. However, more studies are warranted to determine 
the effect of DOPAC and HVA levels in the brain on dopamine utilization in arthritis. 
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Context of This Study 
 Rheumatoid arthritis (RA) is a chronic, debilitating autoimmune disease that causes the 
destruction of bone tissue and the articular structures of joints. Thus, RA is characterized by 
infiltration of inflammatory immune cells, particularly, T-lymphocytes (T cells), macrophages, and 
neutrophils in joints. Activation of microphages immune cells results in the production of 
proinflammatory cytokine, particularly interleukin (IL)-1, IL-6, IL-12 and tumor necrosis factor- 
alpha (TNF-α), which are involved in the up-regulation of inflammatory reactions (Navegantes et al. 
2017). This causes synovial inflammation, eventually leading to joint destruction and disability 
(Gorman & Cope, 2008; Tobon et al., 2010). While the etiology of RA is not well understood, it is 
thought to be a multifactorial disorder involving a complex interplay between genetic, (Kurkó et al., 
2013; Okada et al., 2013;) and environmental factors, such as tobacco smoking (Tobon et al. 2010), 
bodily pain, decreased mobility, fatigue, stiffness, physical disability and the way RA patients have to 
cope with these problems during the activities of daily living, significantly affect their health-related 
quality of life (HR-QOL) (Matcham et al., 2014; Russell, 2008). There is some evidence that RA also 
impacts negatively on mental health (Matcham et al. 2014), indicating that there is a causal 
association between RA and psychiatric disorders (Nicassio, 2010). Psychological disorders in RA 
include depression, anxiety, emotional problems, and overall cognitive dysfunction a phenomenon 
referred to as “brain fog” (Covic et al., 2012; Dickens et al., 2001; Hewlett et al., 2005). Cognitive 
impairment in RA patient population is >30% (Joaquim et al., 2004; Shin et al., 2012;), with a 
majority exhibiting worse cognitive score in psychometric measures for verbal fluency and memory 
(Joaquim et al., 2004). In a longitudinal cohort study, Shin et al. (2012) demonstrated that a 
subgroup of RA patients with cognitive impairment exhibited significantly poor fine motor skills 
than the rest of RA patients. This implied that there should be a correlation between physical 
function and cognitive function in RA. Shin et al. (2013) demonstrated cognitive impairment was 
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significantly associated with greater functional limitations in RA patients, although only depression 
and fatigue (due to coping with functional limitations), were significantly associated with perceived 
cognitive dysfunction. 
 Psychological disorders like depression and anxiety in inflammation disorders are associated 
with chronic peripheral inflammation mediated by pro-inflammatory cytokines (TNFα, IL-1β, and 
IL-6) (Süβ et al., 2015). Initially, cognitive dysfunction in RA patients was thought to be due the 
highly elevated systemic markers of inflammation, particularly C-reactive protein, which can 
potentially damage the integrity of blood-brain barrier thereby causing neuroinflammation (Eagan et 
al., 2012; Elwood et al., 2017). Neuroinflammation was thought to affect hippocampal plasticity, 
which triggers depression as repair response (Süβ et al., 2015; Wager-Smith et al. 2010). However, it 
has been demonstrated recently that hippocampal immunity, cellular plasticity and function are 
maintained despite severe peripheral autoimmune-mediated inflammation (Süβ et al. 2015). By this 
account, it can be inferred that there should be neuronal factors underlying psychological disorders 
in RA rather than systemic inflammations. 
 The neural activities in the brain are mediated by a wide repertoire of neurotransmitters in 
the brain. However, dopamine, gamma-Aminobutyric acid (GABA), and serotonin are among the 
few neurotransmitters frequently studied in relation to mental disorders due to their aggressive 
nature from neuropsychology and interdisciplinary perspectives (Narvaes, & Martins de Almeida, 
2014). Acidic dopamine (DA) is the principal neurotransmitter involved in both the central nervous 
system (CNS) and peripheral nervous system (Basu & Dasgupta, 2000). It is one of the precursors to 
norepinephrine and epinephrine allowing it to be involved in the parasympathetic nervous system 
(PNS) as well. A decline in DA concentration or inhibition of its synthesis or metabolism rates in 
the CNS can result in impairment of critical neurologic functions, such as cognition, behavior and 
fine movements. 
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 Surprisingly, apart from its principle neurotransmitter function in the CNS, DA also has 
some inductive effect on a multitude of T-cells and dendritic cells (DCs), and therefore, regarded as 
a neuroimmunotransmitter. The role of DA in the neural-immune communication has been 
demonstrated in some in vivo studies reviewed previously by Basu and Dasgupta (2000). The studies 
revealed that in vivo injury or stimulation of specific central dopaminergic (DA) system results in the 
suppression or enhancement of functional activities of the immune effector cells, especially T-cells 
and antigen-presenting DCs. While DCs expresses a complete machinery to synthesize and store 
dopamine, regulatory T-cells expresses dopamine receptors (DRs) and, therefore, have the ability to 
release, produce, and uptake dopamine (Pacheco et al. 2014). This underpins dopamine-mediated 
integration of the immune system to the CNS, where dopaminergic immune regulations could be the 
driving force during autoimmunity and associated inflammations (Pacheco et al. 2014). Thus, 
malfunctioned DRs on immune cells including T-cells could also be major cause of overall cognitive 
impairment. Impairment of the DRs implies a blockade of the interaction between T-cells and 
dendritic cells, and therefore, leading to impairment of dopaminergic immune regulations. 
 Monocyte-derived DCs produce DA and store it in vesicles. The interactions between T- 
cells and the DCs affect differentiation, polarization, and the secretion of pro-inflammatory 
cytokines (Levite, 2008). It has been shown (Levite, 2008) that high (10-4 - 10-3M) and medium 
levels (10-7 - 10-5 M) of DA are toxic to the T-cells and can result in unregulated stimulation. 
Through this, it can be inferred that DA affects a multitude of systems. It is necessary to understand 
and quantify the amounts present within these systems to link cognitive impairment to the body. 
However, the total amount DA in CNS includes its two acidic metabolites: 3,4- 
dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). Thus, to better understand the 
amount of DA and its longevity in the brain, it is important to consider its principle acidic 
metabolites. 
4 
 
 The purpose of study was to determine whether there are variations of DA concentration 
and its related catecholamines in rat models of RA compared to healthy controls. Different parts of 
the brain have different neurologic activities. The following amygdala, hypothalamus, front cerebral 
cortex, hippocampus, and cerebellum, which exhibit strong role in memory, balance, emotional 
stability, and overall cognition, were evaluated. The limbic system, which consists of the amygdala 
and hippocampus, was the main area of interest since this is where spatial reasoning, memories, and 
emotional behaviors are affected. The limbic system involves the dopaminergic mesolimbic pathway, 
which is made up of movements from the ventral tegmental area to the nucleus accumbens. This 
pathway along with the function of the two parts of interest has a role in motivation, and reward. A 
difference in catecholamines in any of the affected areas would imply that inflammation, and/or 
pain is not the only contributing source of cognitive impairment in patients with RA. 
Materials and Methods 
 
Animal Model of Human Rheumatoid Arthritis 
 
 Three-month old Male Lewis Rats (n=16) were purchased from Charles River Laboratories 
and maintained at the vivarium in the University of Texas at San Antonio (UTSA). The rats were 
maintained on a 12-hour light/12-hour dark cycle in a temperature and humidity controlled 
environment. 
Adjuvant Induced Arthritis 
 
 The male rats were randomly assigned to one of two groups: control (non-arthritic), or the 
arthritic group. In the arthritic group, arthritis was induced by methods previously described by 
Tanimoto et al., (2015). Briefly, an intradermal injection of 0.01 ml of Freund’s incomplete adjuvant 
(Sigma Aldrich™) was injected on the base of the tail (1 mg heat killed Mycobacterium tuberculosis 
H37Rak, suspended in 1.0 mL of liquid paraffin) at day one and day 7. Arthritis is usually present 
within 7 days after injection of the adjuvant. To confirm arthritis, erythema, swelling, and deformity 
5 
 
of the paw joints was scored by the scale shown in Table 1. With the highest possible score being 16, 
rats with a score > 12 were selected and sacrificed on 28. The schematic presentation of treated and 
control rat models is shown in Figure 1. 
Table 1: Induced-arthritis scoring scale 
 
Score Indication 
0 No erythema or swelling 
1 Slight erythema or swelling of one toe or finger 
2 Erythema and swelling of more than one toe or finger 
3 Erythema and swelling of the ankle or wrist 
4 Complete erythema and swelling of the toes or fingers and the ankle or wrist and an 
inability to bend the ankle or wrist 
 
 
 
  
 
Figure 1: Rat model of adjuvant-induced rheumatoid arthritis (RA) 
 
 
Brain Tissue Preparation 
 
 Once sacrificed by decapitation as mentioned above, five sections of the brain: the amygdala, 
hippocampus, hypothalamus, cerebellum, and front cerebral cortex, were removed using the 
RA Group 
3 month, male, 10 Lewis Rats 
Day 1 
Injection 100 µl Freund’s complete 
adjuvant 
Day 7 
Injection 100 µl Freund’s incomplete 
adjuvant 
Day 28 
Sacrifice 
Control Group 
3 month, male, 10 Lewis Rats 
Day 1 
Injection 100 µl saline 
Day 7 
Injection 100 µl saline 
Day 28 
Sacrifice 
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Stereotaxic Atlas of Paxinos and Watson as a guide. Additional organs of interest (lungs, heart, kidneys, 
and eyes) were also collected, removed, and immediately flash frozen in liquid nitrogen for transport 
to the University of the Incarnate Word (UIW). The organs were then stored at in the -80ºC UIW 
freezer for later analysis. 
Bicinchroninic Acid (BCA) Protein Assay 
 
 Frozen brain tissues were homogenized using a stand homogenizer with 750µL of 0.2N 
perchloric acid buffer. The homogenized brain solutions (homogenates) were then centrifuged at 
10,000 rpm, 4ºC for 10 minutes. The supernatant was transferred to a different tube and the pellet 
discarded. A Microplate BCA Protein Assay Kit, from Thermo Scientific™ was used to calculate the 
total amount of protein in a given sample of tissue homogenate. BCA protein assays were used a 
standardized curve to determine the amount of protein in each individual supernatant. The scheme 
of the standardized curve was as follows: 
Table 2: Dilution scheme for standard test-tube procedure 
 
Vial Volume diluent(µL) Volume and source 
of BSA (µL) 
Final BSA concentration 
(µg/mL) 
A 66 200 of stock 1500 
B 100 100 of stock 1000 
C 100 100 of vial A dilution 750 
D 100 100 of vial B dilution 500 
E 100 100 of vial D dilution 250 
F 100 100 of vial E dilution 125 
G 100 100 of vial F dilution 62.5 
H 100 0 0=Blank 
 
Samples were then be diluted to achieve an overall R2 value of 0.9 or higher. The scheme of the 
sample curve is shown in table 3. 
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Table 3: Dilution scheme for sample test tube procedure 
 
Vial Volume diluent (µL) Volume and source of stock 
sample supernatant (µL) 
Final sample  
concentration (%)  
AS 0 21 100 
BS 7 21 75 
CS 21 21 50 
DS 63 21 25 
 
Once all standard and sample dilution vials were prepared, 9µL of brain samples and standards were 
loaded onto a microplate. 4µL of the compatibility reagent solution was then added to each well and 
incubated for 15 minutes. Then, 260µL of the working reagent solution prepared earlier (50:1 ratio 
of BCA working reagent A to BCA working reagent B provided by Thermo Scientific™) was added 
into each well and allowed to incubate for 30 minutes. A protein gradient then begun to form within 
the wells. Absorbance was then measured at 562nm using the Infinite 200 PRO Nano Quant Tecan 
Microplate Reader. Protein amounts were calculated by plotting the absorbance values read from the 
samples vs. the standardized curve, resulting in the protein concentration of each supernatant in 
µg/mL. 
High Performance Liquid Chromatography (HPLC) 
 
 High Performance Liquid Chromatography (HPLC) was used for quantification of DA, 
HVA, and DOPAC in the brain of both control and arthritic rats. HPLC allows for the distinct 
separation of compounds by carrying the injected supernatant through a packed column (stationary 
phase) with a solvent (mobile phase). As the sample is passed through the column, it interacts 
between the two phases at a different rate. Analytes in the sample that have the least amount of 
interaction with the mobile phase, will elute the column sooner, and pass through the detector at 
different rates, resulting in varied retention times. 
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 A modular design of the Agilent Infinity 1220 HPLC was used since it provides enough 
versatility and integration capabilities to overcome analytical challenges. 100µL of brain sample and 
standards were prepared and directly injected for analysis. A gradient elution table was used to 
ensure clean separation of peaks. Mobile phases consisted of ACN, H2O, and a buffer of 0.1 M 
trifluoroacetic acid (TFA). The mobile phase was used to bring the samples through a Zorbax SB- 
C18 reversed phased column (Agilent technology). Samples were read at a 250nm absorption 
wavelength. Each sample was injected in triplicates at a flow of 0.5µL per minute for ~10 minutes. 
 The area under each sample’s analyte curve compared to that of the standards curve were 
used to determine the concentration of each analyte in ng of specific analyte/ mg of protein. Proper 
storage of the column and rinsing before and after each run was carried out using a solution of 
50/50 methanol to water, to ensure that no carryover of any analyte peak was in sequential runs. 
Statistical Analyses 
 
 The difference in levels of dopamine, DOPAC, HVA in the five different parts of the brain 
of arthritic groups versus non-arthritic controls were compared using t-test and two-way analysis of 
variance (two-way ANOVA) test. Differences between groups were considered to be statistically 
significant at a P value of <0.05. Statistical analyses were performed using GraphPad Prism version 
7.03 for Windows (GraphPad Software, Inc., San Diego, CA, USA, www.graphpad.com).  
 
Results 
 
Adjuvant-Induced Rheumatoid Arthritis 
 
 The levels of dopamine, DOPAC, HVA were measured in the cerebral cortex (CX), 
hippocampus (HIP), hypothalamus (HYP), amygdala (AMG), and cerebellum (CBL) regions of the 
brains of rats with adjuvant-induced rheumatoid arthritis and non-arthritic controls. However, due 
to lack of hypothalamus (HYP) brain tissue samples from the arthritic rats, tests for HYP were 
performed for controls only. Therefore, results for HYP were excluded from the analysis. 
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Protein Levels in Four Parts of the Brain 
 Total protein quantities in brain tissue homogenates were determined using the BCA protein 
assays. The protein quantities in the cerebellum, amygdala, hippocampus, and cerebral cortex were 
estimated for both arthritic (treated) and non-arthritic (control) Lewis rats (Fig. 1). From Figure 1 
below, arthritic rats exhibited higher protein levels than non-arthritic rats in cerebellum, amygdala, 
and hippocampus but not in cerebral cortex. However, t-tests showed that between-group 
difference in protein concentration was not statistically significant for cerebellum (P=0.3414), 
amygdala (P=0.7618), hippocampus (P=0.7834) and cerebral cortex (p=0.7439). Two-way ANOVA 
test demonstrated that neither of the two independent variables (treatment/control and brain 
region) nor their interaction were statistically significant (p>0.05) in influencing the protein levels in 
the four parts of the brain (see Appendix A). 
 
 
 
 
Figure 2: Total protein concentration (ug/ml) brains parts of arthritic (treated) versus non-arthritic 
(control) Lewis rats. The CBL, AMG, and HIP of the treated rats exhibited high protein levels than 
controls, while CX exhibited higher protein levels in controls than treated. The differences were not 
significant across all brain regions (p>0.05) 
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Dopamine Levels in Four Parts of the Brain 
 
 Dopamine concentrations in the four different parts of the brain from both arthritic 
(treated) and non-arthritic (control) Lewis rats were determined using the HPLC (Fig. 3). From 
Figure 3 below, arthritic rats exhibited lower dopamine concentration than non-arthritic rats across 
all the four parts of the brain. This was statistically significant in the cerebellum (P =0.0170) and 
cerebral cortex (0.0095), but not significant in amygdala P=0.2527) and hippocampus (P=0.7779). 
Two-way ANOVA test demonstrated that brain regions (cerebellum, amygdala, hippocampus and 
cerebral cortex) as an independent variable had statistically significant effect on the dopamine 
concentration (P=0.0131), but not its interactions (P=0.4002). On the other hand, treatment and 
control or their interactions did not seem to have any statistically significant effect on the 
distribution of dopamine across the four brain parts (p>0.05) (see Appendix B). 
 
Figure 3: The levels of dopamine in CBL, AMG, HIP and CX. Treated (Arthritic) rats exhibited 
lower levels of dopamine than control rats, the difference being statistically significant for CBL (P 
=0.0170) and CX (0.0095) only. 
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DOPAC Levels in Four Parts of the Brain 
 Using HPLC, the concentration of DOPAC, a metabolite of dopamine, was determined in 
the four different parts of the brain of both arthritic (treated) and non-arthritic (control) Lewis rats 
(Fig. 4). From Figure 4 below, arthritic rats exhibited a lower DOPAC levels than non-arthritic rats 
in amygdala, though not statistically significant (p=0.4314). Both arthritic and non-arthritic Lewis 
rats, exhibited very low concentrations of DOPAC in hippocampus and cerebral cortex, with 
undetectable DOPAC observed in cerebellum of arthritic rats and hippocampus of non-arthritic 
rats. Two-way ANOVA test demonstrated that neither of the two independent variables 
(treatment/control and brain region) or their interaction were statistically significant (p>0.05) (see 
Appendix C). 
 
 
 
 
 
Figure 4: The levels of DOPAC in CBL, AMG, HIP and CX. DOPAC was undetectable in one 
control (HIP) and one treated brain part (CBL). 
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HVA Levels in Four Parts of the Brain 
 
 Using HPLC, the concentration of HVA, a metabolite of dopamine, was determined in four 
different parts of the brains in both arthritic (treated) and non-arthritic (control) Lewis rats (Fig. 4). 
From Figure 4 below, arthritic rats exhibited a significantly lower HVA levels than non-arthritic rats 
in cerebellum (p= 0.0414). On the other hand, arthritic rats exhibited a higher HVA levels than non- 
arthritic rats in hippocampus, though not statistically significant (p= 0.7625). Undetectable HVA 
were observed in amygdala and cerebral cortex of non-arthritic Lewis rats. Two-way ANOVA test 
demonstrated that only a single independent variable (treatment/control and brain region) and its 
interaction were statistically significant (P=0.0046; P=0.0463). On the other hand, the different 
regions of the brain did not seem to significantly influence HVA levels in both arthritic and non- 
arthritic rats (P=0.9601) (see Appendix D). 
 
Figure 5: HVA levels in four parts of the brain. HVA was detected in all the four parts of the brain 
from treated rats. It was however, undetectable in AMG and CX of controls. HVA levels in CBL 
were significantly higher in controls but not in treated mice (p= 0.0414). In hip, HVA was higher in 
treated than controls, though not significant (p= 0.7625). 
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Discussion And Conclusion 
 
 More than 30% of populations of population with RA have cognitive impairments (Shin et 
al. 2012; Joaquim et al. 2004), with a significant subgroup of this RA patients exhibiting worse 
cognitive function in verbal fluency, memory (Joaquim et al. 2004) and poor fine motor skills (Shin 
et al. 2012). This study was based on the overarching hypothesis from the literature that acidic 
dopamine (DA), which is the principal neuroimmunotransmitter linking the immune system to the 
CNS and peripheral nervous system, its changes in the brain produces cognitive impairments in RA. 
Furthermore, this study was also guided by the hypothesis, C-reactive protein (CRP), which is a 
biomarker of cognitive impairment, should be elevated in the brains of RA patients with cognitive 
impairment (Eagan et al. 2012; Elwood et al. 2017). The present study demonstrated variations in 
the levels of both brain protein and DA with its two acidic metabolites (DOPAC and HVA) across 
four parts of the brain: AMG, CX, HIP, and CBL, which are mainly involved in cognition and 
motor function. 
Brain Protein 
 The present study demonstrated elevated levels of total protein CBL, AMG, and HIP of 
arthritic than non-arthritic rats, while CX exhibited higher protein levels in non-arthritic than 
arthritic rats. Although not significant (p>0.05), the protein elevations in most of the brain regions 
of arthritic rats indicated that the proteins could be associated with cognitive impairment in RA. 
There several brain proteins involved in cognitive function or decline, including NPTX2—neuronal 
pentraxin 2 (Xiao et al. 2017), CRP (Eagan et al. 2012), albumin (Llewellyn et al. 2010). However, 
low levels of NPTX2 and albumin have been associated with cognitive impairment and neurological 
diseases, such as Alzheimer’s Disease, in the elderly population (Llewellyn et al. 2010; Xiao et al. 
2017). Although the present study did not characterize and identify the elevated protein components 
in the arthritic rats, CRP, was most likely to be involved (Eagan et al. 2012; Elwood et al. 2017). 
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CRP was elevated in the AMG, which is associated with fear, depression and anxiety disorder 
(Forster et al. 2012); CBL, which coordinates movement, motor learning or timing (Mauk et al. 
2000); and HIP, which regulates emotions (Binder et al. 2012), but not in CX, which regulated high-
level brain functions, such as memory, cognition, and perception. This demonstrates that CRP was 
largely elevated in the limbic system that regulates emotions and therefore, could be largely 
responsible for depression in RA. This was supported by findings from previous studies, which 
demonstrated that depression scores were slightly, but positively correlated with the CRP levels (r 
0.46, P < 0.001) (Kojima et al. 2009), and that CRP was significant predictor of cognitive 
impairment in patients with RA (Shin et al. 2012). However, in the present study, CRP was not 
significantly elevated across the four brain regions of arthritic rats (p>0.05), indicating that it is not 
partly contributes to cognitive impairment. Therefore, there should be neuronal factors that also 
contribute to psychological disorders in RA rather in addition to systemic inflammation marker 
CRP. 
Dopamine 
 Dopamine, a neurotransmitter in the brain that is important in regulating movement, 
emotional responses and sensations of pleasure and pain. It is critically regulating positive emotions 
and motivation (Schultz, 2002), and therefore, low levels in the brain could be involved in cognitive 
dysfunction in RA. Findings in the present study demonstrated that dopamine levels in the arthritic 
rats were generally low across all the four limbic brain regions analyzed, where dopamine levels were 
significantly low in CBL (P =0.0170) and CX (0.0095). There is a paucity of published data directly 
compares the level of dopamine in arthritic-induced rats or RA patients to healthy non-arthritic 
controls. However, low levels and altered dopamine neurotransmission has been observed in 
patients with fibromyalgia, a chronic rheumatic condition characterized by generalized pain, fatigue, 
and dysregulation of emotion. Pain in both fibromyalgia and RA are all attributed to increased levels 
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of proinflammatory cytokines. According to Miller et al. (2013), the levels and function of 
neurotransmitters (including dopamine) are broadly modulated by proinflammatory cytokines, at 
multiple levels. This is achieved by alteration of neurotransmitter synthesis, reuptake and release, via 
the activation of metabolic and epigenetic processes (Miller et al. 2013). Given that autoimmunity is 
coupled to CNS and PNS (Basu & Dasgupta, 2000), and the existence pathways linking systemic 
inflammation to dopaminergic reward system (Sturgeon et al. 2016), dopamine could be centrally 
involved cognitive impairment in autoimmune inflammatory diseases, including RA. According to 
Sturgeon et al. (2016), RA patients are likely to develop alteration in dopaminergic 
neurotransmission, and therefore, likely to develop cognitive and behavioral impairments. 
 This finding suggests that RA patients at increased risk of cognitive impairment can benefit 
from treatment with dopamine agonists (Eijsbouts et al. 1999). However, given that autoimmunity in 
RA is tightly coupled to CNS (Basu & Dasgupta, 2000), dopamine agonists is likely to suppress 
inflammatory response and improve quality of life. A previous case report (Erb et al. 2001), 
demonstrated that treating of unremitting RA with prolactin antagonist cabergoline resulted in a 
significant remission. D1-like dopamine receptor antagonist have been shown to ameliorated the 
severity of collagen-induced arthritis in mice, by promoting anti-inflammatory IFN-γ and inhibiting 
pro-inflammatory interleukin (IL)-17 production by T-cells (Nakashioya et al. 2011). Currently, the 
potential therapeutic benefits of dopamine-agonists are increasingly being studied for human RA. 
DOPAC and HVA Levels 
 DOPAC and HVA are the acid metabolites of dopamine, and therefore, their levels in the 
brain should correlate with the utilization of dopamine in the brain. Findings in the present study, 
demonstrated very low levels of DOPAC in arthritic rats, with some brain parts being below 
detectable limits. However, levels HVA were higher in arthritic rats compare to non-arthritic 
controls. While low DOPAC levels as observed in arthritic rats indicates low utilization of dopamine 
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and low “turnover” of DA in the brain, this does not necessarily imply utilization of dopamine in 
the dopaminergic systems (Ebinger et al. 1987). An early in vivo study of dopamine release and 
metabolism in rat brain regions, demonstrated DOPAC/HVA ratio in varied between brain regions 
in accordance with whole tissue measurements. This is consistent with findings in the present in vivo 
study, which demonstrated varied DOPAC and HVA, levels of the difference regions of the arthritic 
rats. 
Limitations of the Study and Future Perspective 
 
 The present in vivo study is the first to assess protein levels and utilization of 
neurotransmitters in dopaminergic systems in arthritic rats, to assess their roles in cognitive 
impairment in RA. Experimental materials were limited (arthritic rat brain samples) and therefore, it 
was not possible to evaluate the hypothalamus. Furthermore, the calibration standards for DOPAC 
and HVA appeared to be a bit higher, yet DOPAC and HVA are only available in smaller quantities 
than the parent neurotransmitter substance (dopamine). This could explain why some parts of the 
brain had undetectable levels of DOPAC and HVA. This warrants more in vivo studies to re-evaluate 
DOPAC and HVA in arthritic rats using calibration standards of lower concentration. Future, 
studies should focus on the potential therapeutic benefits of dopamine-agonists treating human RA 
and associated risk of cognitive impairment. 
Conclusion 
 A significant subgroup of RA patients is likely to develop cognitive impairment. The present 
study has demonstrated that CRP, dopamine, DOPAC and HVA are involved the neuropathology 
and associated cognitive impairments in RA. Therefore, RA patients at increased risk of cognitive 
impairment can benefit from treatment with dopamine agonists. However, more studies are 
warranted to determine the effect of DOPAC and HVA levels in the brain on dopamine utilization 
in arthritic rats.   
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Appendix A: Two-way ANOVA test of protein levels in four parts of the brain 
 
 
 
 
 
Table Analyzed Two-way ANOVA, not RM    
 
Two-way ANOVA Ordinary     
Alpha 0.05    
 
Source of Variation % of total variation P value P value 
summary 
Significant?  
Interaction 2.655 0.9156 ns No  
Row Factor 53.28 0.0761 ns No  
Column Factor 1.694 0.5872 ns No  
 
ANOVA table SS DF MS F (DFn, DFd) P value 
Interaction 77159 3 25720 F (3, 8) = 
0.1671 
P=0.9156 
Row Factor 1548419 3 516140 F (3, 8) = 3.353 P=0.0761 
Column Factor 49238 1 49238 F (1, 8) = 
0.3198 
P=0.5872 
Residual 1231624 8 153953  
 
Number of missing 
values 
0    
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Appendix B: Two-way ANOVA test of dopamine levels in four parts of the brain 
 
 
 
 
Table Analyzed Two-way ANOVA, not RM     
 
Two-way ANOVA Ordinary     
Alpha 0.05    
 
Source of Variation % of total variation P 
value 
P value 
summary 
Significant?  
Interaction 14.09 0.4002 ns No  
Row Factor 9.424 0.556 ns No  
Column Factor 42.65 0.0131 * Yes  
 
ANOVA table SS DF MS F (DFn, DFd) P value 
Interaction 50.11 3 16.7 F (3, 8) = 1.11 P=0.4002 
Row Factor 33.53 3 11.18 F (3, 8) = 
0.7427 
P=0.5560 
Column Factor 151.7 1 151.7 F (1, 8) = 
10.08 
P=0.0131 
Residual 120.4 8 15.05  
 
Number of missing 
values 
0    
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Appendix C: Two-way ANOVA test of DOPAC levels in four parts of the brain 
 
 
Table Analyzed Two-way ANOVA, not RM    
 
Two-way ANOVA Ordinary     
Alpha 0.05    
 
Source of Variation % of total variation P 
value 
P value summary Significant?  
Interaction 19.89 0.4609 ns No  
Row Factor 16.86 0.525 ns No  
Column Factor 7.455 0.3314 ns No  
 
ANOVA table SS DF MS F (DFn, DFd) P value 
Interaction 132 3 43.98 F (3, 8) = 
0.9507 
P=0.4609 
Row Factor 111.9 3 37.29 F (3, 8) = 
0.8059 
P=0.5250 
Column Factor 49.46 1 49.46 F (1, 8) = 1.069 P=0.3314 
Residual 370.1 8 46.27  
 
Number of missing 
values 
0    
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Appendix D: Two-way ANOVA test of HVA levels in four parts of the brain 
 
 
Table Analyzed Two-way ANOVA, not RM    
 
Two-way ANOVA Ordinary     
Alpha 0.05    
 
Source of Variation % of total variation P value P value summary Significant?  
Interaction 58.9 0.0046 ** Yes  
Row Factor 25.15 0.0463 * Yes  
Column Factor 0.00532 0.9601 ns No  
 
ANOVA table SS DF MS F (DFn, DFd) P value 
Interaction 50.71 3 16.9 F (3, 8) = 9.85 P=0.0046 
Row Factor 21.65 3 7.216 F (3, 8) = 4.205 P=0.0463 
Column Factor 0.004581 1 0.004581 F (1, 8) = 
0.002669 
P=0.9601 
Residual 13.73 8 1.716  
 
Number of missing 
values 
0    
 
